Neon Bloom, Inc. (NBCO)
USD 0.01
(-7.0%)
USD 0.01
(-7.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 389.56 Thousand USD | -3.34% |
| 2022 | 403 Thousand USD | -69.82% |
| 2021 | 1.33 Million USD | 1438.56% |
| 2020 | 86.78 Thousand USD | -99.58% |
| 2019 | 20.52 Million USD | 4515.43% |
| 2018 | 444.69 Thousand USD | -17.14% |
| 2017 | 536.67 Thousand USD | 1266130.18% |
| 2016 | 42.38 USD | 0.0% |
| 2010 | 1.13 Million USD | -1.36% |
| 2009 | 1.15 Million USD | 16.61% |
| 2008 | 989.03 Thousand USD | -26.62% |
| 2007 | 1.34 Million USD | 3036.23% |
| 2006 | 42.97 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 12.52 Thousand USD | -93.9% |
| 2024 Q2 | 1.16 Million USD | 9185.53% |
| 2023 Q2 | -6212.00 USD | -113.51% |
| 2023 Q1 | 45.99 Thousand USD | 308.79% |
| 2023 Q4 | 205.31 Thousand USD | 4.64% |
| 2023 FY | 389.56 Thousand USD | -3.34% |
| 2023 Q3 | 196.19 Thousand USD | 3258.39% |
| 2022 Q1 | 109.09 Thousand USD | -90.59% |
| 2022 FY | 403 Thousand USD | -69.82% |
| 2022 Q4 | 11.25 Thousand USD | -81.14% |
| 2022 Q3 | 59.67 Thousand USD | -82.57% |
| 2022 Q2 | 342.33 Thousand USD | 213.8% |
| 2021 Q4 | 1.15 Million USD | 1417.01% |
| 2021 Q3 | 76.38 Thousand USD | 59.53% |
| 2021 Q2 | 47.88 Thousand USD | -39.06% |
| 2021 Q1 | 78.56 Thousand USD | 3732.49% |
| 2021 FY | 1.33 Million USD | 1438.56% |
| 2020 Q3 | 50.61 USD | 0.0% |
| 2020 FY | 86.78 Thousand USD | -99.58% |
| 2020 Q4 | 2050.00 USD | 3950.58% |
| 2019 FY | 20.52 Million USD | 4515.43% |
| 2018 FY | 444.69 Thousand USD | -17.14% |
| 2017 Q3 | 34.10 USD | 0.0% |
| 2017 FY | 536.67 Thousand USD | 1266130.18% |
| 2017 Q4 | 34.10 USD | 0.0% |
| 2016 FY | 42.38 USD | 0.0% |
| 2016 Q3 | 6.26 USD | 0.0% |
| 2016 Q4 | 6.26 USD | 0.0% |
| 2015 Q4 | 3.53 USD | 0.0% |
| 2015 Q3 | 3.53 USD | 0.0% |
| 2011 Q1 | 118.88 Thousand USD | -71.31% |
| 2010 Q1 | 293.58 Thousand USD | 35.26% |
| 2010 Q2 | 224.72 Thousand USD | -23.45% |
| 2010 Q3 | 210.07 Thousand USD | -6.52% |
| 2010 Q4 | 414.35 Thousand USD | 97.24% |
| 2010 FY | 1.13 Million USD | -1.36% |
| 2009 Q2 | 322.47 Thousand USD | 4.16% |
| 2009 FY | 1.15 Million USD | 16.61% |
| 2009 Q4 | 217.05 Thousand USD | -29.76% |
| 2009 Q3 | 309.02 Thousand USD | -4.17% |
| 2009 Q1 | 309.6 Thousand USD | 18.21% |
| 2008 Q4 | 261.9 Thousand USD | -7.23% |
| 2008 FY | 989.03 Thousand USD | -26.62% |
| 2008 Q3 | 282.31 Thousand USD | 30.06% |
| 2008 Q2 | 217.05 Thousand USD | -4.69% |
| 2008 Q1 | 227.74 Thousand USD | -51.75% |
| 2007 Q1 | 227.31 Thousand USD | 0.0% |
| 2007 Q2 | 351.31 Thousand USD | 54.55% |
| 2007 Q3 | 297.07 Thousand USD | -15.44% |
| 2007 Q4 | 472.03 Thousand USD | 58.89% |
| 2007 FY | 1.34 Million USD | 3036.23% |
| 2006 FY | 42.97 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 70.828% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 92.274% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 98.682% |
| Nascent Biotech, Inc. | 2.22 Million USD | 82.53% |
| Rebus Holdings, Inc. | 664 Thousand USD | 41.33% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 98.954% |
| Qrons Inc. | 643.67 Thousand USD | 39.478% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.322% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 6.237% |
| Skye Bioscience, Inc. | 13.54 Million USD | 97.124% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.551% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 92.079% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -48.845% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.545% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 86.641% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 74.062% |
| Mesoblast Limited | 5.9 Million USD | 93.399% |
| Marizyme, Inc. | 19.23 Million USD | 97.975% |
| Genus plc | 147.7 Million USD | 99.736% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 95.563% |
| Pharming Group N.V. | 225.49 Million USD | 99.827% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 80.985% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 70.961% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 95.328% |
| ContraFect Corporation | 56.88 Million USD | 99.315% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 91.164% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 73.656% |
| IMV Inc. | 37.7 Million USD | 98.967% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 86.039% |
| MultiCell Technologies, Inc. | 567.42 USD | -68555.67% |
| ONE Bio Corp. | 6.44 Million USD | 93.954% |
| Accustem Sciences Inc. | 3.74 Million USD | 89.602% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.547% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 26.768% |
| Q BioMed Inc. | 3.43 Million USD | 88.664% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 98.424% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 85.174% |
| Biomind Labs Inc. | 994.18 Thousand USD | 60.815% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.608% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 77.862% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 94.201% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 79.105% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1658.264% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 97.567% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 78.771% |
| GB Sciences, Inc. | 1.42 Million USD | 72.576% |
| Alpha Cognition Inc. | 9.7 Million USD | 95.986% |
| HST Global, Inc. | 140.9 Thousand USD | -176.47% |
| CSL Limited | 3.44 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 65.369% |
| Halberd Corporation | 74.84 Thousand USD | -420.518% |
| Enzolytics Inc. | 2.17 Million USD | 82.126% |
| Agentix Corp. | 1.37 Million USD | 71.601% |
| Resverlogix Corp. | 12.71 Million USD | 96.935% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 89.329% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.975% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 62.685% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 83.801% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 75.334% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 88.559% |
| AVAX Technologies, Inc. | 7.31 Million USD | 94.671% |
| Zenith Capital Corp. | 8.94 Million USD | 95.644% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.953% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -2136.186% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 84.134% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -127.14% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 79.72% |
| Kadimastem Ltd | 2.41 Million USD | 83.836% |
| Helix BioMedix, Inc. | 1.97 Million USD | 80.245% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 96.415% |
| BioStem Technologies, Inc. | 22.97 Million USD | 98.304% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -114.655% |
| LadRx Corporation | 3.81 Million USD | 89.78% |
| Cell Source, Inc. | 4.32 Million USD | 90.993% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 57.817% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 57.817% |
| NovAccess Global Inc. | 2.46 Million USD | 84.207% |
| Affymax, Inc. | 39.38 Million USD | 99.011% |
| Itoco Inc. | 919.14 Thousand USD | 57.616% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 90.809% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 65.186% |
| Mobile Lads Corp. | 554.54 Thousand USD | 29.75% |
| CytoDyn Inc. | 18.05 Million USD | 97.843% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1447.801% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -77.013% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 72.562% |
| SYBLEU INC | 160.87 Thousand USD | -142.153% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 78.552% |
| International Stem Cell Corporation | 5.27 Million USD | 92.609% |
| Bioxytran, Inc. | 3.82 Million USD | 89.802% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -640.029% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1814.988% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 98.926% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 75.923% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 47.058% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 87.478% |
| Neutra Corp. | 243.82 Thousand USD | -59.775% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 97.768% |
| PureTech Health plc | 144.59 Million USD | 99.731% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 98.099% |
| IXICO plc | 4.7 Million USD | 91.724% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 95.572% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.669% |
| CSL Limited | 3.89 Billion USD | 99.99% |
| Cellectis S.A. | 97.32 Million USD | 99.6% |